Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd Triplett(Livestrong Foundation), Kendra Garrison(The University of Texas at Austin), Nicholas Marshall(Merck & Co., Inc., Rahway, NJ, USA (United States)), Moses Donkor(The University of Texas at Austin), John Blazeck(The University of Texas at Austin), Candice Lamb(The University of Texas at Austin), Ahlam N. Qerqez(The University of Texas at Austin), Joseph D. Dekker(The University of Texas at Austin), Yuri Tanno(The University of Texas at Austin), Wei-Cheng Lu(The University of Texas at Austin), Christos S. Karamitros(The University of Texas at Austin), Kyle Ford(The University of Texas at Austin), Bing Tan(The University of Texas at Austin), Xiaoyan M. Zhang(Q Therapeutics (United States)), Karen McGovern(Q Therapeutics (United States)), Sílvia Coma(Q Therapeutics (United States)), Yoichi Kumada(Kyoto Institute of Technology), Mena S Yamany(The University of Texas at Austin), Enrique Sentandreu(The University of Texas at Austin), George Fromm(Heat Biologics (United States)), Stefano Tiziani(The University of Texas at Austin), Taylor H. Schreiber(Heat Biologics (United States)), Mark Manfredi(Q Therapeutics (United States)), Lauren I. R. Ehrlich(The University of Texas at Austin), Everett Stone(The University of Texas at Austin), George Georgiou(Livestrong Foundation)
Cited by 302